Stockwinners Market Radar for September 08, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:23 EDT Dell Technologies exec Rothberg sells over 30,000 class C shares - In a regulatory filing, Dell Technologies general counsel and secretary Richard Rothberg disclosed the sale of 30,009 class C common shares of the company on September 6 at a price of $68 per share.

17:01 EDT Aesthetic Medical receives noncompliance notification from Nasdaq - Aesthetic Medical announced that it has received a notification letter from Nasdaq, notifying the company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.

16:41 EDT Moderna urges shareholders to reject TRC Capital's 'mini-tender' offer - Moderna has been notified that TRC Capital Investment Corporation has made an unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price of $107.56 per share. TRC Capital's offer price of $107.56 per share is approximately 4.44% lower than the closing price of Moderna common stock on the Nasdaq Global Select Market on September 1, 2023, the last trading day prior to the date of the offer, September 5, 2023. Moderna does not endorse TRC Capital's unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to TRC Capital's offer because the offer is at a price below the current market value of Moderna common stock and is subject to numerous conditions.

16:15 EDT Everest Group raises quarterly dividend to $1.75 from $1.65 per share - Everest Group, Ltd. announced that its Board of Directors declared an increase in the regular quarterly dividend from $1.65 to $1.75 per common share. This dividend will be payable on or before September 29, 2023 to all shareholders of record as of September 19, 2023.

16:01 EDT AssetMark Financial names Michael Kim CEO - AssetMark Financial announced that, in line with the AssetMark Board of Directors' established succession plan, Michael Kim has been named the company's new Chief Executive Officer, effective immediately. Kim will also join the AssetMark Board of Directors. In connection with this announcement, Natalie Wolfsen will depart the company to pursue another opportunity. "Michael is an experienced, highly effective leader who brings a wealth of expertise and perspective to his new role," said Xiaoning Jiao, Chairperson of the AssetMark Board of Directors. "During his tenure at AssetMark, he has demonstrated his ability to drive consistently strong results. His knowledge of AssetMark, understanding of the needs of our clients, and uniquely advisor-focused lens will undoubtedly benefit the company as it continues its growth and evolution."

15:10 EDT Burford sees being entitled to 35% of any proceeds generated in Petersen case - Burford Capital stated in connection with the September 8 Findings of Fact and Conclusions of Law issued by the United States District Court for the Southern District of New York in connection with the Petersen and Eton Park cases against the Republic of Argentina and YPF: "Subject to final computations by the parties' experts, that finding implies interest of approximately $6.8M for Petersen and $815M for Eton Park, yielding a total judgment of approximately $14.3B for Petersen and $1.7B for Eton Park, or $16B in total... The Court has asked the parties to submit a proposed judgment reflecting the Ruling, which Plaintiffs will endeavor to do promptly. Once that judgment issues, Argentina has indicated its intention to appeal. There is also a process for seeking reconsideration from the District Court of its own ruling, although such motions rarely prevail as they are being made to the same judge who decided the matter originally. Once the Court issues its final judgment, that judgment will be appealable as of right to the Second Circuit Court of Appeals. The Second Circuit presently is taking around a year to resolve appeals once filed, although there is meaningful deviation from that mean. The District Court's judgment would be enforceable while the appeal is pending unless Argentina posts a bond to secure its performance, which we consider unlikely, or unless a court grants a relatively unusual stay. Following the Second Circuit's decision, either party can seek review from the Supreme Court of the United States. The Supreme Court accepts cases only on a discretionary basis and we believe the likelihood of it accepting a commercial case of this nature that does not present a contested issue of law is quite low, particularly given that Argentina has already once in this Case unsuccessfully sought Supreme Court review. With an enforceable judgment in hand, Plaintiffs will either need to negotiate a resolution of the matter with Argentina, which would certainly result in what would likely be a substantial discount to the judgment amount in exchange for agreed payment, or engage in an enforcement campaign against Argentina which would likely be of extended duration relying on Burford's and its advisors' judgment enforcement expertise. Burford will not provide publicly any information about its enforcement or settlement strategies... Burford has different economic arrangements in each of the Petersen and Eton Park cases. At bottom, on a net basis, we expect that the Burford balance sheet will be entitled to around 35% of any proceeds generated in the Petersen case and around 73% of any proceeds generated in the Eton Park case. In the Petersen case, Burford is entitled by virtue of a financing agreement entered into with the Spanish insolvency receiver of the Petersen bankruptcy estate to 70% of any recovery obtained in the Petersen case. That 70% entitlement is not affected by Burford's spending on the cases, which is for Burford's account; it is a simple division of any proceeds. From that 70%, certain entitlements to the law firms involved in the case and other case expenses will need to be paid, reducing that number to around 58%. Burford has, however, sold 38.75% of its entitlement in the Petersen case to third party investors, reducing Burford's net share of proceeds to around 35% (58% x 61.25%). In the Eton Park case, there is both a funding agreement and a monetization transaction. The net combined impact of those transactions is that Burford would expect to receive around 73% of any proceeds. Burford has not sold any of its Eton Park entitlement. In both Petersen and Eton Park, the numbers above are approximations and will vary somewhat depending on the ultimate level of case costs by the end of the Case, as we expect continued significant spending on the Case."

15:00 EDT Riot Platforms calls CNBC headline 'sensational and inaccurate' - Riot Platforms issued a statement in response to recent inquiries regarding its power strategy following its August monthly operations update. "In particular, on September 6, 2023, CNBC published a story titled Texas paid bitcoin miner Riot $31.7 million to shut down during heat wave in August," the company said. "Unfortunately, this sensational and inaccurate headline has caused confusion, which we would like to dispel. In August, Riot provided over 84,000 megawatt hours of energy to the market in Texas to reduce overall demand, lower consumer prices, and stabilize the grid during a heat wave. This ensured that consumers did not experience disruptions during extreme temperatures. Riot earned approximately $7 million from the Electric Reliability Council of Texas, Inc. ("ERCOT") ancillary services program. ERCOT is a membership-based independent system operator, which operates about ninety percent of the electric grid in Texas, helping to deliver power to 25 million customers across a geographic area larger than most countries. ERCOT's primary responsibilities are to maintain system reliability, facilitate competitive wholesale and retail energy markets, and to ensure open access to power transmission. The ancillary services program is a competitive bidding process in which certain large customers in ERCOT's market bid for the grid operator to pay them a fee that is similar to an insurance premium, which then affords ERCOT the right to control the customer's electrical load to ensure grid stability. Riot's premium amounts to less than one percent of the program, which administered nearly $1 billion during this time period. Riot also sold approximately $24 million of pre-purchased energy to its energy provider, TXU, pursuant to its long-term power purchase agreements. TXU is a retail electricity provider and subsidiary of Vistra Corp., which is a publicly traded enterprise valued at over $12 billion. When economically efficient to do so, Riot does not use the energy it has purchased for business operations and instead sells it back to TXU in exchange for credits to apply to future energy bills."

13:56 EDT Dish says Hearst demands 'unreasonable' as local channels removed - Dish Network (DISH) stated in a press release: "Despite Dish Network's efforts to negotiate in good faith, Hearst Television, Inc. has forced a channel blackout on DISH TV removing customers' access to 37 local channels in 27 markets. Dish has been in discussions with Hearst for months working to reach an agreement to keep its channels on air for customers. Instead, Hearst is demanding tens of millions of dollars in rate increases that would affect customers, while it devalues its product by making programming available elsewhere, even as viewership declines... Hearst's unreasonable demands for its current channels and programming on DISH, along with declining viewership and sharing its content on other platforms, further demonstrates the disconnect between programming providers and distributors. Other recent examples of programmers using the same anti-consumer tactics are Nexstar with DirecTV and Disney with Charter... Hearst's action affects viewers of various ABC, NBC, CBS, CW, MNT and IND channels across 27 markets."

13:29 EDT Barclays up nearly 1% after Bloomberg report on trading division job cuts - Shares of Barclays are up 0.9% in afternoon trading after Bloomberg's Jan-Henrik Forster, Harry Wilson and Irina Angh reported that the company plans to cut "hundreds" of jobs as soon as next week and will dismiss about 5% of client-facing staff in the trading division. People familiar with the matter told Bloomberg that the lender is also preparing to restructure teams within its U.K. consumer-banking unit. "We do not comment on speculation. We regularly review our operations to ensure we meet the evolving needs of our customers and clients in an efficient and effective way," Barclays said in a statement to Bloomberg. Reference Link

13:02 EDT Baker Hughes reports U.S. rig count up 1 to 632 rigs

12:32 EDT New York sees refunds from Charter for lost Disney channels - New York Governor Kathy Hochul directed the Department of Public Service to hold Charter (CHTR) "accountable and ensure the company delivers refunds for New York consumers who have experienced disrupted service" amid the ongoing cable dispute between Charter and Disney (DIS). Nearly 15M cable viewers nationwide and more than 1.5M in New York State lost access to ESPN and other Disney-owned channels on August 31 when Disney and Charter were unable to renew a distribution deal. Governor Hochul has directed the Department of Public Service "to ensure Charter is providing customers with appropriate refunds for any period that customers cannot access Disney-owned channels during the dispute." Reference Link

12:00 EDT Phreesia falls -9.9% - Phreesia is down -9.9%, or -$2.33 to $21.31.

12:00 EDT RH falls -13.5% - RH is down -13.5%, or -$49.85 to $318.70.

12:00 EDT Sunlands Online rises 18.5% - Sunlands Online is up 18.5%, or $1.24 to $7.95.

11:57 EDT Sanofi treatment of phenylketonuria granted FDA orphan status - The FDA granted orphan status to Sanofi US Services' adeno-associated virus-based vector with an engineered capsid serotype SNY001 harboring human phenylalanine hydroxylase cDNA as a treatment of phenylketonuria. Reference Link

11:36 EDT Stellantis says wage raises totaling 14.5% offered to UAW in contract proposal - Stellantis released a letter From Mark Stewart, North America COO, to employees regarding the company's first economic proposal to the UAW, which states in part: "This has been a really good week at the bargaining table. We have made tremendous progress on hundreds of issues at the subcommittee level and I'm proud of the work our team has accomplished to get us to this point. Today, we took an important next step in this process by presenting the UAW with our first economic proposal. From the start of these negotiations, we have said we're committed to fairly rewarding you for your hard work and contributions to the success of the company. Today's offer includes significant wage increases in each year of the contract and, in percentage terms, this opening offer is larger than where we ultimately landed in 2019. We wanted to share the details with you because we feel it is important to be transparent about what is currently on the table. Here are the highlights: For 'most represented employees,' wage increases in each year of the contract totaling 14.5% (no lump sums)... This is a responsible and strong offer that positions us to continue providing good jobs for our employees today and in the next generation here in the U.S. It also protects the company's future ability to continue to compete globally in an industry that is rapidly transitioning to electric vehicles. Because we know this is important to you and your families, we remain committed to bargaining in good faith and reaching a fair agreement by the deadline. With this equitable offer, we are seeking a timely resolution to our discussions."

11:32 EDT Global Net Lease: Preliminary results show stockholders approve merger proposals - Global Net Lease (GNL) held a previously announced Special Meeting of Stockholders. Preliminary results indicate that stockholders approved both proposals, including the issuance of GNL shares of common stock pursuant to the Agreement and Plan of Merger with the Necessity Retail REIT (RTL) and the other parties thereto and the previously announced Internalization Agreement. As a result, depending on the results of special meeting of the stockholders of RTL today, and the satisfaction or waiver of all closing conditions, the merger with RTL and the internalization are expected to close on September 12, 2023. Final voting results are subject to verification by the independent inspector of election and will be reported on a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission within four business days.

11:22 EDT Argentina ordered to pay at least $8.4B in YPF suit with claims owned by Burford - Argentina was ordered to pay at least $8.4B in damages in a U.S. lawsuit over its 2012 re-nationalization of state oil company YPF SA (YPF) in an order issued by U.S. District Judge Loretta Preska in the U.S. District Court for the Southern District of New York. The judge awarded the amount to entities backed by litigation funder Burford Capital (BUR), which acquired the right to pursue the claims for $16.6M in 2015. The decision states in addition: "The Court also rejects the Republic's effort to inject Burford Capital into these proceedings. This remains a case brought by plaintiffs against a defendant for its wrongful conduct towards them, and the relevant question is what the Republic owes Plaintiffs to compensate them for the loss of the use of their money, not what Plaintiffs have done or will do with what they are owed. The Republic owes no more or less because of Burford Capital's involvement." "Argentina has already pledged to appeal, which will likely delay payment for months or even years, but could also complicate its efforts to return to global debt markets," according to Bloomberg's reporting on the decision that was posted to the court's website. Reference Link

11:05 EDT Super League Gaming announces name change, 1-for-20 reverse stock split - Super League Gaming announced at its annual general meeting, shareholders approved a name change to Super League Enterprise, Inc. and a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-20. "The company believes the new name better aligns with the full vision and potential for the company's proficiency in providing a scalable, vertically integrated publishing engine for the immersive web. The name change will not affect the status of the company or the rights of any stockholders in any respect, or the validity or transferability of stock certificates presently outstanding. In connection with the name change, expected to go into effect on September 11, the stock trading symbol will be changed from 'SLGG' to 'SLE' to more closely align the ticker symbol with the company's new name... The reverse split is expected to become legally effective at 12:01 AM on September 11 and the shares are expected to begin trading on the split-adjusted basis on The Nasdaq Capital Market under the Company's new trading symbol 'SLE' on September 11, upon The Nasdaq Stock Market's approval. On the legal effective date, every 20 issued and outstanding shares of the company's common stock will be converted automatically into one share of the company's common stock without any change in the par value per share. Once effective, the reverse split will reduce the number of shares of common stock outstanding from approximately 71.9M shares to approximately 3.59M. The company strongly believes a reverse split is necessary to increase the market price per share to better assure that it maintains compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market... and to make investments in the company more attractive to investors by increasing the trading price of the company's common stock on such market," Super League stated.

10:48 EDT Virgin Galactic announces take-off of 'Galactic 03' flight - Virgin Galactic tweeted: "We have take-off at 8:34am MDT #Galactic03" Reference Link

10:35 EDT LQR House announces commencement of share buyback program - LQR House announces that the previously disclosed share buyback program, approved by the board of directors, has officially gone into effect today. The company has instructed Dominari Securities to initiate the repurchase of shares today, Friday, September 8, marking the commencement of "this pivotal phase." Sean Dollinger, CEO of LQR House, said, "We've seen all the chatter, and we understand how crucial this buyback is for all our shareholders. Today marks the first day we are legally able to repurchase stock in LQR House Inc. We plan to provide the public with updates on the results of this initiative next week."

10:07 EDT Trinseo trading resumes

10:00 EDT Hudson Pacific falls -6.6% - Hudson Pacific is down -6.6%, or -48c to $6.92.

10:00 EDT Sunlands Online rises 8.2% - Sunlands Online is up 8.2%, or 55c to $7.26.

10:00 EDT Smartsheet rises 10.3% - Smartsheet is up 10.3%, or $4.17 to $44.53.

09:47 EDT Instructure falls -4.4% - Instructure is down -4.4%, or -$1.12 to $24.16.

09:47 EDT RH falls -6.5% - RH is down -6.5%, or -$23.95 to $344.60.

09:47 EDT Guidewire rises 9.5% - Guidewire is up 9.5%, or $8.03 to $92.86.

09:41 EDT Aeglea Biotherapeutics trading resumes

09:36 EDT Aeglea Biotherapeutics trading halted, volatility trading pause

09:26 EDT Safe & Green receives Nasdaq approval to list real estate development subsidiary - Safe & Green announced that Nasdaq has approved the company's application to list the common stock of Safe and Green Development Corporation, the company's real estate development subsidiary, on the Nasdaq Stock Market under the symbol "SGD".

09:23 EDT UPS to raise average prices by 5.9% in 2024 - Effective December 26, 2023, UPS (UPS) said Daily Rates for its services will increase. "This helps to support ongoing expansion and capability enhancements as we strive to maintain the high service levels you expect from UPS," the company said on its website. UPS added that the rates for UPS Ground, UPS Air and International services will increase an average net 5.9%. The Fly notes that FedEx previously announced that FedEx Express shipping rates will increase by an average of 5.9% for U.S. domestic, U.S. export, and U.S. import services. FedEx Ground and FedEx Home Delivery shipping rates will increase by an average of 5.9%. FedEx Ground Economy shipping rates will also increase. FedEx Freight shipping rates will increase by an average of 5.9%-6.9% dependent on the customer's transportation rate scale. Reference Link

09:09 EDT Coherus Biosciences completes Surface Oncology acquisition - Coherus BioSciences announced the closing of the previously announced acquisition of Surface Oncology. As a result of the acquisition, Coherus' novel I-O pipeline now includes four differentiated clinical-stage assets: Toripalimab, a late-stage, anti-PD-1 monoclonal antibody candidate under BLA review for the potential treatment of advanced recurrent or metastatic nasopharyngeal carcinoma; Casdozokitug, a novel, first-in-class IL-27-targeted antibody currently being evaluated in Phase 2 clinical trials in lung cancer and liver cancer; CHS-114, a highly selective, competitively positioned, ADCC-enhanced CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors; and CHS-006, a TIGIT-targeted antibody currently in a Phase 1/2 study in combination with toripalimab in patients with advanced solid tumors. At the closing of the acquisition, Coherus issued 0.1960 shares of its common stock per share of outstanding Surface common stock and certain outstanding Surface employee equity awards for a total value equal to approximately $66.9 million, the sum of $40 million plus Surface's net cash at closing of the transaction of $26.9 million. Surface shareholders also received contingent value rights or 70% of milestone and royalty-based value of existing programs with Novartis and GSK, as well as for 25% of upfront payments made pursuant to potential ex-US licensing agreements for CHS-114 and 50% of upfront payments made pursuant to potential ex-US licensing agreements for casdozokitug, subject to certain deductions as set forth in the contingent value rights agreement. Amounts under these CVRs are payable for a period of ten years following the closing of this transaction. As a result of the acquisition, Surface has become a wholly owned subsidiary of Coherus and the common stock of Surface will no longer be listed for trading on the Nasdaq Capital Market, effective as of prior to market open on September 8, 2023.

09:02 EDT Intelligent Bio plans to add ketamine, tramadol to fingerprint drug test - Intelligent Bio Solutions announced the successful completion of a key development milestone in its plans to add ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System. New assays for testing both drugs have passed the Company's initial design phase and are ready for scale-up and transfer to manufacture in preparation for potential clinical trials. After completing these activities and successful clinical trials, the assays can be added to the panel of substances detected by the Company's proprietary drug screening system.

08:47 EDT Marathon Digital announces private exchanges of $147M of convertible notes - Marathon Digital Holdings announced that the Company has entered into privately negotiated exchange agreements with certain holders of its 1.00% Convertible Senior Notes due 2026 to exchange approximately $417 million aggregate principal amount of the Notes held by such holders for an aggregate of approximately 26.2 million newly issued shares of Marathon common stock, pursuant to an exemption from registration provided in Section 4(a)(2) of the Securities Act of 1933, as amended. Marathon will not receive any cash proceeds from the issuance of the shares of its common stock, and the final number of shares that Marathon will issue will be determined over a number of days. Marathon will also pay investors in cash for accrued and unpaid interest on the exchanged Notes. In certain circumstances during a short period following today's announcement the transaction size could be reduced or the entire transaction could be canceled. After completing the Exchanges approximately $331 million aggregate principal amount of the Notes will remain outstanding. The Exchanges could affect the market price of Marathon's common stock.

08:41 EDT Breeze Holdings announces preliminary tabulations for special meeting - Breeze Holdings Acquisition announced that in connection with its upcoming Special Meeting of Stockholders, the Company has already received proxies representing approximately 75.8% of the Company's total outstanding shares to approve the proposal to extend the date by which the Company must consummate a business combination until as late as June 26, 2024. This is well in excess of the percentage of votes required to approve the Proposal. However, please note that all proxies received by the Company may be revoked at any time before they are exercised at the Special Meeting, which is scheduled to be held on September 22, 2023, at 10:00 a.m. Eastern Time. The purpose of the Proposal is to allow the Company additional time to complete its initial business combination. As previously announced on November 1, 2022, the Company entered into a merger agreement and plan of reorganization with TV Ammo, Inc., an advanced technology and composite manufacturing company based in Garland, Texas, pursuant to which a newly-formed wholly-owned subsidiary of the Company will merge with and into TV Ammo, with TV Ammo surviving as a wholly-owned subsidiary of the Company. Upon closing of the transaction, the Company will be renamed "True Velocity, Inc." and its common stock is expected to trade on the Nasdaq Capital Market. In connection with the proposed transaction, the Company intends to file with the U.S. Securities and Exchange Commission a registration statement on Form S-4 that will include a proxy statement of the Company and that also will constitute a prospectus of True Velocity, Inc. with respect to the shares of True Velocity, Inc. common stock to be issued in the proposed transaction. The Company had previously expected the transaction to close in the fourth quarter of 2023. TV Ammo is continuing to prepare financial statements in accordance with the auditing standards of the Public Company Accounting Oversight Board, which process is ongoing and has taken more time than was previously expected. As a result, the Company now anticipates filing the Proxy Statement/Prospectus in the third quarter of 2023 and now expects the transaction to close in the first quarter of 2024, subject to the satisfaction of customary closing conditions, including certain regulatory and shareholder approvals.

08:37 EDT CSX appoints Kevin Boone as CCO - CSX also announced that Kevin Boone, previously executive vice president of Sales and Marketing, is named executive vice president and chief commercial officer. The new title recognizes Boone's breadth of existing responsibilities across CSX's broad customer base and growing offering of supply chain solutions. Boone previously led the company's finance organization before transitioning to sales and marketing in 2021.

08:35 EDT BioRestorative Therapies annnounces activation of Northwell Health in cLDD trial - BioRestorative Therapies announced that Northwell Health, New York State's largest health care provider, has been activated and can now start recruitment in the State of New York for BioRestorative's ongoing Phase 2 clinical trial targeting chronic lumbar disc disease. BioRestorative and Northwell Health entered into a clinical trial agreement in May with regard to the Phase 2 trial. Much effort and collaboration have taken place and, now that site specific training is complete, the site can initiate patient recruitment and enrollment. BRTX-100, the Company's lead clinical candidate, is a novel cell-based therapeutic engineered to target areas of the body that have little blood flow and limited oxygen supply. It is currently being evaluated in connection with the Company's ongoing Phase 2 clinical trial targeting cLDD. The trial is prospective, randomized, double-blinded and controlled. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100, with 40 million cells injected into the lumbar disc that is causing pain. A total of up to 99 eligible patients will be randomized at up to 15 clinical sites in the United States to receive either the investigational drug or control in a 2:1 fashion. BioRestorative recently completed its safety run-in phase of the Phase 2 trial and is now openly enrolling patients across all its clinical sites located throughout the United States.

08:33 EDT Perimeter Medical Imaging AI appoints Hodges as VP, Sales and Marketing - Perimeter Medical Imaging AI announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, VP, Sales and Marketing, effective immediately. Most recently, Hodges was Vice President of Sales at SIA Health.

08:31 EDT Phunware appoints Mike Snavely as CRO - Phunware announced that Mike Snavely has been hired as the Company's Chief Revenue Officer, effective September 12, 2023. Mike most recently served as the General Manager of Vidable AI in Madison, Wisconsin.

08:21 EDT Fastenal reports August sales up 3.6% to $668.16M - Yesterday, Fastenal reported August sales of $668.159M versus $644.727M in the same month of last year. Fastenal reported August daily sales of $29.05M, up 3.6% versus 2022. Reference Link

08:18 EDT Forza X1 completes beta test sea trial of F22 boat - Forza X1 announced the completion of its latest beta test sea trial on Lake James in North Carolina last week. Announced back in March 2023, Forza's F22 will be the first Forza product offered for consumer sale and has been regularly tested and refined in preparation for its official launch. During the sea trial, Forza's engineering team conducted comprehensive tests of the F22. Key highlights include: Range and Engine Performance Validation: The Company tested the range and engine performance of the F22, ensuring they align with motor specifications. Software Control Enhancements: The Forza team introduced a series of software control enhancements designed to improve the F22's throttle response, system diagnostics, and battery cooling and monitoring. Real World Testing: The sea trial also focused on assessing the F22 and its propulsion system under real-world conditions on Lake James.

08:13 EDT Biocept, Plus Therapeutics enter licensing agreement for CNSide - Biocept (BIOC) announced the signing of a non-exclusive licensing agreement for CNSide with Plus Therapeutics, Inc. (PSTV), which expands the laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases, which is cancer in the membranes that surround the brain and spinal cord. CNSide is Biocept's proprietary cerebrospinal fluid-based tumor cell capture and enumeration platform used in detecting, quantifying, and monitoring tumor status in LM. This new agreement allows for Plus to perform CNSide testing during its clinical trials and commercially, subject to regulatory approval. Biocept will provide expertise, including consulting on equipment and materials sourcing, as well as providing the necessary technology and training to perform CNSide. Plus will pay Biocept an upfront fee of $150,000 in stock, plus $6,000 per CSF tumor cell enumeration analysis performed in Biocept's CLIA-certified and CAP-accredited laboratory prior to the completion of the technology transfer. Once the technology transfer is complete, Plus will pay Biocept $300,000 plus fees on a sliding scale starting at $2,800 for each CNSide test they perform. The license agreement also gives Plus the option to negotiate for third-party exclusivity with a $1M payment to Biocept.

08:13 EDT Skye Bioscience signs MOU with Prime Minister of the Republic of Serbia - SK bioscience announced that Ana Brnabi, Prime Minister of the Republic of Serbia has visited the SK bioscience headquarters and signed a memorandum of understanding with the company to establish a strategic partnership in vaccine development and manufacturing between the two countries. Along with the MOU, SK bioscience, and Frontier Biopharma agreed to sign a contract within the year for collaborating to establish vaccine manufacturing facilities in Serbia with support from the Serbian government. According to the MOU, SK bioscience will utilize its own vaccine R&D, manufacturing, and commercialization capabilities for strengthening the vaccine manufacturing environment to a global-certified level, transferring technologies and know-how for pandemic preparedness, commercializing products, training human resources, and supporting the vaccine R&D in Serbia. The newly established platform will supply Serbia and other European and emerging markets from a hub in Serbia.

08:11 EDT Nasdaq receives SEC approval to launch Dynamic M-ELO - Nasdaq has received SEC approval to launch Dynamic Midpoint Extended Life Order, the first exchange Artificial Intelligence powered order type. Nasdaq's M-ELO matches like-minded counterparties with longer-term investing horizons on a broker-neutral SEC-regulated Exchange by requiring each party to a trade to wait a short period of time before trading. Dynamic M-ELO will leverage Artificial Intelligence to provide real-time changes to holding periods for M-ELO participants, which is set to improve fill rates and reduce market impact. The order type applies an AI model with over 140 factors and offers an average combined volume-weighted improvement of over 30% in testing. Dynamic M-ELO simultaneously enhances both liquidity and execution quality improvement outcomes, usually considered mutually exclusive, by adjusting dynamically to real-time market conditions.

08:09 EDT Vivid Seats completes acquisition of Wavedash - Vivid Seats has completed the acquisition of WD Holdings in an all-cash transaction. Wavedash is an online secondary ticket marketplace in Japan with a market-leading position and accretive Adjusted EBITDA margins. The effect of approximately four months of contribution from Wavedash was contemplated in Vivid Seats' financial guidance provided on August 8. Wavedash will be included within the Marketplace segment.

08:08 EDT WiMi Hologram Cloud developed metasurface eyepiece - WiMi Hologram Cloud announced that a metasurface eyepiece for augmented reality has been developed, which is based on metasurfaces composed of artificially fabricated subwavelength structures. The metasurface eyepiece employs a special optical design and engineered anisotropic optical response to achieve an ultra-wide field of view, full-color imaging, and high-resolution near-eye display.

08:07 EDT Citius receives regulatory guidance from U.S. FDA on BLA for LYMPHIR - Citius Pharmaceuticals announces the Company has received additional guidance from the U.S. Food and Drug Administration, FDA, regarding the planned resubmission of the Company's Biologics License Application, BLA, for LYMPHIR, an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma, CTCL, after at least one prior systemic therapy. The FDA has agreed with the Company's plans to address the requirements outlined in the complete response letter received July 28, 2023. The guidance from the FDA provides Citius with a path for completing the necessary activities to support the resubmission of the Company's Biologics License Application for denileukin diftitox. No additional clinical efficacy or safety trials have been requested by FDA for the resubmission. "We are encouraged by the constructive engagement with the FDA," stated Leonard Mazur, Chairman and CEO of Citius. "Based on the clear feedback from the FDA, Citius plans to complete the CRL remediation activities by the end of the year and file the resubmission in early 2024. We do not expect these efforts will impact our cash runway."

08:04 EDT Berry Global announces review of strategic alternatives for HH&S segment - Berry announced that it has initiated a formal process to evaluate strategic alternatives for its Health, Hygiene and Specialties segment, or HH&S. HH&S is a provider of nonwovens, specialty films, and tapes for a broad range of end markets, including healthcare, hygiene, consumer, building and construction, and industrials. The company is considering a wide range of available alternatives to maximize shareholder value, including, but not limited to, a sale, strategic partnership or joint venture, spin-off to shareholders, or other separation transaction for some or all of the businesses within HH&S. Importantly, the company expects current members of the HH&S leadership team will continue to lead the business in any anticipated outcome.

08:01 EDT Kroger has agreed to pay $1.2B to states, $36M to tribes for abatement efforts - The Kroger has reached an agreement in principle with plaintiffs to settle the majority of opioid claims that have been or could be brought against the Company by states, subdivisions, and Native American tribes. Along with the execution of certain non-monetary conditions that remain in discussion, Kroger has agreed to pay up to $1.2B to states and subdivisions and $36M to Native American tribes in funding for abatement efforts, and approximately $177M to cover attorneys' fees and costs. The timing of the settlement payments over multiple years, most of which are tax deductible, results in an after-tax net present value to Kroger of approximately $870M. Initial payments would begin in December 2023. Kroger expects to recognize a $1.4B charge during the second quarter of 2023, which will negatively impact earnings per diluted share of $1.54 on a GAAP basis. This does not affect adjusted earnings per diluted share results for 2023, which are provided on a basis that excludes adjustment items. States, subdivisions, and the Native American tribes will have an opportunity to opt-in to participate in the settlement, and Kroger will have full discretion to determine whether there is sufficient participation for the settlement to become effective. If all conditions are satisfied, the settlement would allow for the full resolution of all claims on behalf of participating states, subdivisions and tribes. This settlement is not an admission of wrongdoing or liability by Kroger and Kroger will continue to vigorously defend against any other claims and lawsuits relating to opioids that the final agreement does not resolve.

07:39 EDT Gol Linhas reports preliminary August ASK up 7.7%, total seats up 21.7% - GOL Linhas Aereas Inteligentes announces preliminary air traffic figures for the month of August 2023, compared to the same period in 2022. Highlights: GOL's total supply, ASK, increased 7.7%. Total seats increased 21.7% and the number of departures increased by 17.8%. GOL's total demand increased by 11.6% and the load factor was 84.4%. GOL's domestic supply increased 9.4% and demand increased by 13.7%. GOL's domestic load factor was 84.6%. The volume of departures increased by 18.1% and seats increased by 21.8%. GOL's international supply was 298 million, the demand was 246 million and international load factor was 82.7%.

07:31 EDT BridgeBio reports inducement grants under Nasdaq listing rule - BridgeBio Pharma announced that on September 06, 2023, the compensation committee of BridgeBio's board of directors granted twenty-four new employees restricted stock units for an aggregate of 154,186 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2024, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019 and amended and restated on February 10, 2023.

07:19 EDT NeuBase board does not believe special dividend will enhance shareholder value - NeuBase Therapeutics issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation and their subsequent press release issued on September 6, 2023. "The NeuBase Board of Directors appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value. The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetryx requested in their press release. The Board and management will continue to seek an open and active dialogue with its shareholders, including Symetryx."

07:17 EDT Halozyme informed by Roche of delay in projected Tecentriq SC launch in U.S. - In a regulatory filing yesterday, Halozyme Therapeutics (HALO) disclosed that on September 6, the company was informed by its collaboration and license partner, F. Hoffmann-La Roche, Ltd. (RHHBY), that there will be a delay in the projected launch timing for Tecentriq SC, with ENHANZE in the U.S. "This delay is a result of the need to update Tecentriq SC CMC processes. These updates are expected to be completed in 2023 and are expected to support a potential launch of Tecentriq SC in the U.S. in 2024. There is no expected impact on ex-U.S. filings for Tecentriq SC," Halozyme stated.

07:14 EDT BriaCell reports patient survival, clinical benefit in metastatic breast cancer - BriaCell Therapeutics announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients. "The promising survival data of BriaCell's combination regimen suggests the potential for an industry-shaping leap in advanced metastatic breast cancer treatment," stated Carmen Calfa, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami, Associate Professor of Clinical Medicine, and Principal Clinical Investigator of the Phase 2 Bria-IMT plus check point inhibitors study. "The overall safety profile and survival data in advanced metastatic breast cancer is extremely encouraging in this heavily pre-treated patient population." Phase 2 Combination Study of Bria-IMT with Immune Check Point Inhibitor: The Phase 2 study is fully enrolled. To date, 46 heavily pre-treated advanced metastatic breast cancer patients have been enrolled in the study evaluating BriaCell's lead clinical candidate, Bria-IMT, and immune check point inhibitor combination regimen. 29 patients have received treatment since 2022. Our findings are summarized below. Tolerability: The tolerability of the treatment regimen remains excellent with no dose limiting toxicities. Survival Update: 21 out of 29 patients that have received treatment since 2022 remain alive suggesting tolerability and survival efficacy. The data is not yet mature as patients continue to remain on the study. Median overall survival rate in all patients has been recorded at 13.5 months using Kaplan-Meier curve method which measures the probability of patients' survival in time. The overall survival in advanced breast cancer patients is very limited, 6.7-9.8 months in publications that evaluated similar patients. The survival findings support BriaCell's hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT and support using this combination regimen for our upcoming pivotal study in advanced breast cancer.

07:10 EDT Perella Weinberg Partners appoints Troy Broderick as partner - Perella Weinberg Partners (PWP) announced that Troy Broderick has joined the Firm as a Partner in the Advisory Business. Based in New York, Mr. Broderick will lead business focused on shareholder engagement and activism and will also focus on complex and contested M&A across all sectors globally. Broderick joins PWP from Goldman Sachs (GS). He most recently served as COO of their Global Mergers and Acquisitions business, where he focused on shareholder activism and M&A capital markets.

07:07 EDT OKYO Pharma completes enrollment in Phase 2 trial of OK-101 - OKYO Pharma has completed full enrollment of patients in the randomized portion of the Phase 2 multi-center, double-masked, placebo-controlled clinical trial of topical ocular OK-101 to treat DED. A total of 240 patients have been enrolled in the study. "This trial began in May of this year, and we have been pleased with the rapid pace of enrollment in the trial which has been managed by our clinical development partner Ora Inc., a world leader in dry eye clinical research," said Gary Jacob, Ph.D., CEO of OKYO Pharma. "We now have 240 patients enrolled in the trial and are anticipating the last-patient last-visit to occur in the last week of November 2023, with the planned release of top-line data occurring in December 2023."

07:03 EDT Asbury Automotive to acquire Jim Koons Automotive Companies - Asbury Automotive signed a definitive agreement to acquire Jim Koons Automotive Companies, the ninth largest privately-owned dealership group in the U.S. The sale of the Mid-Atlantic Region company is one of the most sizable in auto retail history, representing over $3B in revenue in 2022 and includes 20 dealerships, 29 franchises, six collision centers and one of the highest volume Toyota and Stellantis dealerships in the US. Asbury currently operates 138 dealerships, representing 31 domestic and foreign brands, as well as 32 collision repair centers. Kerrigan Advisors was the exclusive sell-side advisor on the transaction, representing Koons. The transaction is subject to customary closing conditions and is expected to close in the fourth quarter of 2023 or early in the first quarter of 2024. Asbury plans to fund the purchase price with its existing liquidity, credit facility and cash on hand.

07:01 EDT Well Health, Orion Health announce strategic global partnership - WELL Health Technologies announces a strategic global partnership with Orion Health. This alliance, founded on mutual expertise and vision, seeks to set enhanced standards in health integration tools to benefit the broader public health sector. Together, these two industry leaders are focused on reshaping the healthcare landscape by driving patient empowerment and reducing administrative burdens for healthcare providers. Both companies are Integrating health information across the continuum of care, reducing the burden on healthcare providers and empowering patients with tools that support more active participation in their healthcare. This partnership will leverage the experience of Orion Health's decade of research and development in data science and machine learning, which led to the release of its Orchestral intelligence platform. "We are thrilled to embark on this global partnership with Orion Health" said Shane Sabatino, CPO and Head of Public Sector Partnerships WELL "Our joint commitment to leveraging technology for the betterment of healthcare aligns perfectly with the evolving needs of the industry. Our suite of solutions, including online appointment booking, e-referral, and EMR-based Telehealth products, are now available to Orion Health's customers."

06:05 EDT ChipMOS reports August revenue $57.5M, up 6.9% - ChipMOS reported its unaudited consolidated revenue for the month of August. Revenue for the month of August was $57.5M, representing a slight decrease of 0.2% from July and an increase of 6.9% from August 2022. The company noted August's high single-digit year-over-year revenue growth, which was essentially flat on a month-over-month basis, reflects additional stabilization in loading levels of its DDIC high-end test platform, and further signs of improvement in its Memory business.

05:35 EDT Nvidia, Reliance Industries announce pact to advance AI in India - Nvidia and Reliance Industries announced a collaboration to develop India's own foundation large language model trained on the nation's diverse languages and tailored for generative AI applications to serve the world's most populous nation. The companies will work together to build AI infrastructure that is over an order of magnitude more powerful than the fastest supercomputer in India. Nvidia will provide access to the most advanced Nvidia GH200 Grace Hopper Superchip and Nvidia DGX Cloud, an AI supercomputing service in the cloud. GH200 marks a fundamental shift in computing architecture that provides exceptional performance and massive memory bandwidth.

05:02 EDT Caesars opens sportsbook in Lexington - Caesars, in partnership with Keeneland and Red Mile Gaming & Racing, celebrated the grand opening of Caesars Sportsbook at Red Mile earlier. The more than 4,600-square-foot sportsbook in Lexington is the only retail sportsbook in Central Kentucky. Governor Andy Beshear placed the ceremonial first bet alongside chairman Jonathan Rabinowitz of the Kentucky Horse Racing Commission, Caesars, Keeneland, and Red Mile representatives.